Chemoinformatics : concepts, methods, and tools for drug discovery
暂无分享,去创建一个
[1] Gilles Klopman,et al. META, 3. A Genetic Algorithm for Metabolic Transform Priorities Optimization , 1997, J. Chem. Inf. Comput. Sci..
[2] Yi Han,et al. Predicting Caco-2 Cell Permeation Coefficients of Organic Molecules Using Membrane-Interaction QSAR Analysis , 2002, J. Chem. Inf. Comput. Sci..
[3] M. Dickins,et al. Quantitative Structure-Activity Relationships (QSARs) Within Substrates of Human Cytochromes P450 Involved in Drug Metabolism , 2001, Drug metabolism and drug interactions.
[4] Nenad Trinajstić,et al. Predicting Inhibition of Microsomal p-Hydroxylation of Aniline by Aliphatic Alcohols: A QSAR Approach Based on the Weighted Path Numbers , 2001 .
[5] Ferenc Darvas. QSAR in Environmental Toxicology. Edited by Klaus L. E. Kaiser. D. Reidel Publishing Company, Dordrecht/Boston/Lancaster, 1986 , 1987 .
[6] G. Klebe,et al. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.
[7] Alexander D. MacKerell,et al. An Empirical Potential Energy Function for Phospholipids: Criteria for Parameter Optimization and Applications , 1996 .
[8] F. Sanz,et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. , 1993, Molecular pharmacology.
[9] D. Lewis,et al. Molecular dimensions of the substrate binding site of cytochrome P-448. , 1986, Biochemical pharmacology.
[10] James J. P. Stewart,et al. Application of localized molecular orbitals to the solution of semiempirical self‐consistent field equations , 1996 .
[11] J. Gasteiger,et al. FROM ATOMS AND BONDS TO THREE-DIMENSIONAL ATOMIC COORDINATES : AUTOMATIC MODEL BUILDERS , 1993 .
[12] V. Stella,et al. Pro-drugs as Novel Drug Delivery Systems , 1975 .
[13] N. L. Johnson,et al. Multivariate Analysis , 1958, Nature.
[14] P. Labute,et al. Flexible alignment of small molecules. , 2001, Journal of medicinal chemistry.
[15] John H. Holland,et al. Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence , 1992 .
[16] Roberto Todeschini,et al. MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: A comparative 3D QSAR study in a series of steroids , 1997, J. Comput. Aided Mol. Des..
[17] Michael J. E. Sternberg,et al. Evidence That Aspartic Acid 301 Is a Critical Substrate-Contact Residue in the Active Site of Cytochrome P450 2D6 (*) , 1995, The Journal of Biological Chemistry.
[18] Jin-Young Park,et al. Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. , 2003, Journal of medicinal chemistry.
[19] Emili Besalú,et al. Fast Computation of Cross-Validated Properties in Full Linear Leave-Many-Out Procedures , 2001 .
[20] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[21] Michael Sjöström,et al. Chemometrics, present and future success , 1998 .
[22] C. Waller,et al. Comparative molecular field analysis of polyhalogenated dibenzo-p-dioxins, dibenzofurans, and biphenyls. , 1992, Journal of medicinal chemistry.
[23] C. Hansch,et al. QSAR of P450 oxidation: on the value of comparing kcat and km with kcat/km. , 1996, Drug metabolism reviews.
[24] Gilles Klopman,et al. META. 2. A Dictionary Model of Mammalian Xenobiotic Metabolism , 1994, J. Chem. Inf. Comput. Sci..
[25] A. Hopfinger,et al. Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism , 1997 .
[26] Anthony Long,et al. Computer systems for the prediction of xenobiotic metabolism. , 2002, Advanced drug delivery reviews.
[27] J. Shao. Linear Model Selection by Cross-validation , 1993 .
[28] R. Cramer,et al. Recent advances in comparative molecular field analysis (CoMFA). , 1989, Progress in clinical and biological research.
[29] Barry C Jones,et al. Development of a combined protein and pharmacophore model for cytochrome P450 2C9. , 2002, Journal of medicinal chemistry.
[30] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[31] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[32] M Karplus,et al. Evolutionary optimization in quantitative structure-activity relationship: an application of genetic neural networks. , 1996, Journal of medicinal chemistry.
[33] Maurice Dickins,et al. Quantitative Structure-Activity Relationships (QSARs) Within Series of Inhibitors for Mammalian Cytochromes P450 (CYPs) , 2001, Journal of enzyme inhibition.
[34] C. McDiarmid. SIMULATED ANNEALING AND BOLTZMANN MACHINES A Stochastic Approach to Combinatorial Optimization and Neural Computing , 1991 .
[35] D F Lewis,et al. A retrospective evaluation of COMPACT predictions of the outcome of NTP rodent carcinogenicity testing. , 1995, Environmental health perspectives.
[36] D. Lewis,et al. A quantitative structure–activity relationship analysis on a series of alkyl benzenes metabolized by human cytochrome P450 2E1 , 2003, Journal of biochemical and molecular toxicology.
[37] W. Richards,et al. Self-organizing molecular field analysis: a tool for structure-activity studies. , 1999, Journal of medicinal chemistry.
[38] Tudor I. Oprea,et al. Virtual Screening in Lead Discovery: A Viewpoint† , 2002, Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry.
[39] P R Ortiz de Montellano,et al. The substrate specificity of cytochrome P450cam. , 1998, Bioorganic & medicinal chemistry.
[40] W. Trager,et al. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. , 1999, Biochemistry.
[41] Hugo Kubinyi,et al. Quantitative Structure–Activity Relationships in Drug Design , 2002 .
[42] D. Lewis,et al. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. , 2000, Toxicology.
[43] S. Free,et al. A MATHEMATICAL CONTRIBUTION TO STRUCTURE-ACTIVITY STUDIES. , 1964, Journal of medicinal chemistry.
[44] C. Ioannides,et al. The cytochromes P-448--a unique family of enzymes involved in chemical toxicity and carcinogenesis. , 1987, Biochemical pharmacology.
[45] Paul R. Yarnold,et al. Reading and Understanding Multivariate Statistics , 1995 .
[46] Grazyna D. Szklarz,et al. Secobarbital-mediated Inactivation of Cytochrome P450 2B1 and Its Active Site Mutants , 1996, The Journal of Biological Chemistry.
[47] R. Clark,et al. Consensus scoring for ligand/protein interactions. , 2002, Journal of molecular graphics & modelling.
[48] M C Nicklaus,et al. Conformational changes of small molecules binding to proteins. , 1995, Bioorganic & medicinal chemistry.
[49] V. Kulkarni,et al. Three‐Dimensional Quantitative Structure—Activity Relationship (QSAR) and Receptor Mapping of Cytochrome P‐45014αDM Inhibiting Azole Antifungal Agents. , 1999 .
[50] H. Hotelling. Analysis of a complex of statistical variables into principal components. , 1933 .
[51] C. Ioannides,et al. An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation. , 1998, Drug metabolism reviews.
[52] C Masimirembwa,et al. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. , 2000, Biochemical and biophysical research communications.
[53] Stephen Ploch,et al. Induction of hepatic aromatase by p,p′-DDE in adult male rats , 2001, Molecular and Cellular Endocrinology.
[54] H. van de Waterbeemd,et al. Can the Internet help to meet the challenges in ADME and e-ADME? , 2002, SAR and QSAR in environmental research.
[55] C. Marcus,et al. Quantitative Structure‐Activity Relationships in the Displacement of the Dihydrosafrole Metabolite‐Cytochrome P‐450 Complex , 1985 .
[56] S. Wold,et al. Partial Least Squares Projections to Latent Structures (PLS) in Chemistry , 2002 .
[57] Johann Gasteiger,et al. The Coding of the Three-Dimensional Structure of Molecules by Molecular Transforms and Its Application to Structure-Spectra Correlations and Studies of Biological Activity , 1996, J. Chem. Inf. Comput. Sci..
[58] D. Parke,et al. Further evaluation of COMPACT, the molecular orbital approach for the prospective safety evaluation of chemicals. , 1998, Mutation research.
[59] S. Ekins,et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.
[60] A. Cavalli,et al. A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. , 2001, Journal of medicinal chemistry.
[61] A. Hopfinger. A QSAR investigation of dihydrofolate reductase inhibition by Baker triazines based upon molecular shape analysis , 1980 .
[62] C. Ioannides,et al. Quantitative structure–activity relationships in a series of endogenous and synthetic steroids exhibiting induction of CYP3A activity and hepatomegaly associated with increased DNA synthesis , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[63] Alexander D. MacKerell. Molecular Dynamics Simulation Analysis of a Sodium Dodecyl Sulfate Micelle in Aqueous Solution: Decreased Fluidity of the Micelle Hydrocarbon Interior , 1995 .
[64] S H Unger,et al. On model building in structure-activity relationships. A reexamination of adrenergic blocking activity of beta-halo-beta-arylalkylamines. , 1973, Journal of medicinal chemistry.
[65] D A Smith,et al. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[66] Zbigniew Michalewicz,et al. Genetic Algorithms + Data Structures = Evolution Programs , 1992, Artificial Intelligence.
[67] S. Ekins,et al. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[68] Thomas A. Halgren,et al. Merck molecular force field. IV. conformational energies and geometries for MMFF94 , 1996, J. Comput. Chem..
[69] Antti Poso,et al. A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors , 2001, J. Comput. Aided Mol. Des..
[70] S. Ekins,et al. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.
[71] C. Lemmen,et al. FLEXS: a method for fast flexible ligand superposition. , 1998, Journal of medicinal chemistry.
[72] Sean Ekins,et al. Three‐Dimensional Quantitative Structure Activity Relationship for Cyp2d6 Substrates , 2002 .
[73] F ROSENBLATT,et al. The perceptron: a probabilistic model for information storage and organization in the brain. , 1958, Psychological review.
[74] Sean Ekins,et al. In vitro and pharmacophore insights into CYP3A enzymes. , 2003, Trends in pharmacological sciences.
[75] Matthias Rarey,et al. Small Molecule Docking and Scoring , 2001 .
[76] J. Halpert,et al. A Rational Approach to Re-engineer Cytochrome P450 2B1 Regioselectivity Based on the Crystal Structure of Cytochrome P450 2C5* , 2003, The Journal of Biological Chemistry.
[77] Jeffrey P. Jones,et al. A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. , 2000, Journal of medicinal chemistry.
[78] A. Wood,et al. Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test. , 1995, British journal of clinical pharmacology.
[79] F. Guengerich,et al. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.
[80] M. Karplus,et al. Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors. , 1996, Journal of medicinal chemistry.
[81] A. Rettie,et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.
[82] K. Korzekwa,et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.
[83] Christian Lemmen,et al. Computational methods for the structural alignment of molecules , 2000, J. Comput. Aided Mol. Des..
[84] J. E. Schultz. Biotransformation von Arzneimitteln, Band 3. Von S. Pfeifer. 560 S. Verlag Chemie, Weinheim, 1980. Lw. DM 118,— , 1980 .
[85] J. Freidman,et al. Multivariate adaptive regression splines , 1991 .
[86] C Skoda,et al. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.
[87] H. van de Waterbeemd,et al. ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.
[88] Glen Eugene Kellogg,et al. HINT: A new method of empirical hydrophobic field calculation for CoMFA , 1991, J. Comput. Aided Mol. Des..
[89] D. Lewis,et al. Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions , 2002, Xenobiotica; the fate of foreign compounds in biological systems.
[90] D. F. Lewis,et al. Application of process chemistry and SAR modelling to the evaluation of health findings of lower olefins. , 2001, Chemico-biological interactions.
[91] A. Balaban. Highly discriminating distance-based topological index , 1982 .
[92] J B Houston,et al. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. , 1999, British journal of clinical pharmacology.
[93] P. Labute,et al. Binary Quantitative Structure—Activity Relationship (QSAR) Analysis of Estrogen Receptor Ligands. , 1999 .
[94] Gilles Klopman,et al. META. 1. A Program for the Evaluation of Metabolic Transformation of Chemicals , 1994, J. Chem. Inf. Comput. Sci..
[95] S. Chatterjee,et al. Regression Analysis by Example , 1979 .
[96] G. Cruciani,et al. Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .
[97] S A van Acker,et al. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.
[98] S. Pickett,et al. GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.
[99] T. Wobbes,et al. Comparative MO-QSAR studies in various species including man. , 1996, Chemico-biological interactions.
[100] T. Halgren. MMFF VI. MMFF94s option for energy minimization studies , 1999, J. Comput. Chem..
[101] P A Kollman,et al. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. , 2001, Journal of medicinal chemistry.
[102] William L. Jorgensen,et al. OPLS ALL-ATOM MODEL FOR AMINES : RESOLUTION OF THE AMINE HYDRATION PROBLEM , 1999 .
[103] Gisbert Schneider,et al. A fast virtual screening filter for cytochrome P450 3A4 inhibition liability of compound libraries , 2002 .
[104] György M. Keserü,et al. A virtual high throughput screen for high affinity cytochrome P450cam substrates. Implications for in silico prediction of drug metabolism , 2001, J. Comput. Aided Mol. Des..
[105] György M Keseru,et al. A neural network based virtual screening of cytochrome P450 3A4 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.
[106] M J Sternberg,et al. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. , 1991, Carcinogenesis.
[107] R. Huber,et al. Accurate Bond and Angle Parameters for X-ray Protein Structure Refinement , 1991 .
[108] Asuka Nanbo,et al. Mechanistic Study on N‐Demethylation Catalyzed with P450 by Quantitative Structure Activity Relationship using Electronic Properties of 4‐Substituted N,N‐Dimethylaniline , 2002 .
[109] A. Leach. Molecular Modelling: Principles and Applications , 1996 .
[110] C. Ioannides,et al. A quantitative structure-activity relationship study on a series of 10 para-substituted toluenes binding to cytochrome P4502B4 (CYP2B4), and their hydroxylation rates. , 1995, Biochemical pharmacology.
[111] B D Silverman,et al. Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition. , 1996, Journal of medicinal chemistry.
[112] D. Lewis,et al. Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s. , 2002, Toxicology.
[113] Philip N. Judson,et al. Representation of Chemical Structures in Knowledge‐Based Systems: The StAR System. , 1997 .
[114] John Shorter,et al. Linear Free Energy Relationships (LFER) , 2002 .
[115] J. Gasteiger,et al. ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .
[116] G. Crippen,et al. Prediction of Physicochemical Parameters by Atomic Contributions. , 1999 .
[117] D. Lewis,et al. Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. , 1998, Toxicology.
[118] Anton J. Hopfinger,et al. Prediction of Ligand—Receptor Binding Free Energy by 4D‐QSAR Analysis: Application to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase. , 2000 .
[119] H. Wiener. Structural determination of paraffin boiling points. , 1947, Journal of the American Chemical Society.
[120] A. I. Archakov,et al. Cytochrome P450 database for prediction of drugs' fate in living systems , 1995 .
[121] Bernard F. Buxton,et al. Drug Design by Machine Learning: Support Vector Machines for Pharmaceutical Data Analysis , 2001, Comput. Chem..
[122] David F. V. Lewis,et al. Molecular modeling of human cytochrome P450–substrate interactions , 2002, Drug metabolism reviews.
[123] Gunnar Rätsch,et al. An introduction to kernel-based learning algorithms , 2001, IEEE Trans. Neural Networks.
[124] T Ishizaki,et al. Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. , 2003, British journal of clinical pharmacology.
[125] F. Guengerich,et al. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. , 1985, Cancer research.
[126] D. Lewis,et al. Interaction of a series of nitriles with the alcohol-inducible isoform of P450: computer analysis of structure-activity relationships. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.
[127] A. J. Hopfinger. INHIBITION OF DIHYDROFOLATE REDUCTASE: STRUCTURE-ACTIVITY CORRELATIONS OF 2,4-DIAMINO-5-BENZYLPYRIMIDINES BASED UPON MOLECULAR SHAPE ANALYSIS , 1981 .
[128] W. Dunn,et al. Principal components analysis and partial least squares regression , 1989 .
[129] Ferran Sanz,et al. THEORETICAL STUDY ON THE METABOLISM OF CAFFEINE BY CYTOCHROME P-450 1A2 AND ITS INHIBITION , 1994 .
[130] Gabriele Cruciani,et al. Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. , 2003, Journal of medicinal chemistry.
[131] Gianpaolo Bravi,et al. Application of MS‐WHIM Descriptors: 1. Introduction of New Molecular Surface Properties and 2. Prediction of Binding Affinity Data , 2000 .
[132] M. Pastor,et al. A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure--activity relationship analysis. , 1997, Journal of medicinal chemistry.
[133] Max Dobler,et al. 5D-QSAR: the key for simulating induced fit? , 2002, Journal of medicinal chemistry.
[134] N. Metropolis,et al. Equation of State Calculations by Fast Computing Machines , 1953, Resonance.
[135] Kjeld Rasmussen,et al. The Consistent Force Field. 5. PEF95SAC: Optimized potential energy function for alcohols and carbohydrates , 1997 .
[136] N. Vermeulen,et al. Computer prediction and experimental validation of cytochrome P4502D6-dependent oxidation of GBR 12909. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[137] Tudor I. Oprea,et al. Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors , 1996, J. Comput. Aided Mol. Des..
[138] M Pastor,et al. Reliability of comparative molecular field analysis models: effects of data scaling and variable selection using a set of human synovial fluid phospholipase A2 inhibitors. , 1997, Journal of medicinal chemistry.
[139] B G Lake,et al. Quantitative structure--activity relationships for inducers of cytochromes P450 and nuclear receptor ligands involved in P450 regulation within the CYP1, CYP2, CYP3 and CYP4 families. , 2002, Toxicology.
[140] D. F. V. Lewis,et al. Molecular modelling of the human glucocorticoid receptor (hGR) ligand-binding domain (LBD) by homology with the human estrogen receptor α (hERα) LBD: quantitative structure–activity relationships within a series of CYP3A4 inducers where induction is mediated via hGR involvement , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[141] Thomas A. Halgren. Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94 , 1996, J. Comput. Chem..
[142] Peter Willett,et al. EVA: A Novel Theoretical Descriptor for QSAR Studies , 2002 .
[143] J. Halpert,et al. Structural basis of selective cytochrome P450 inhibition. , 1995, Annual review of pharmacology and toxicology.
[144] M H Tarbit,et al. Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[145] Hua Gao,et al. Application of BCUT Metrics and Genetic Algorithm in Binary QSAR Analysis , 2001, J. Chem. Inf. Comput. Sci..
[146] Bryan F. J. Manly,et al. Multivariate Statistical Methods : A Primer , 1986 .
[147] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[148] John Fox,et al. Using New Reasoning Technology in Chemical Information Systems , 1996, J. Chem. Inf. Comput. Sci..
[149] A. Becke. Density-functional thermochemistry. III. The role of exact exchange , 1993 .
[150] Jeffrey P. Jones,et al. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[151] David F V Lewis,et al. A quantitative structure-activity relationship (QSAR) study of mutagenicity in several series of organic chemicals likely to be activated by cytochrome P450 enzymes. , 2003, Teratogenesis, carcinogenesis, and mutagenesis.
[152] T. Halgren. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular‐interaction energies and geometries , 1999, Journal of computational chemistry.
[153] Johann Gasteiger,et al. Superposition of Three-Dimensional Chemical Structures Allowing for Conformational Flexibility by a Hybrid Method , 1998, J. Chem. Inf. Comput. Sci..
[154] C. Hansch,et al. An analysis of the structure-activity relationship in the adrenergic blocking activity of the beta-haloalkylamines. , 1968, Biochemical pharmacology.
[155] P. Maurel,et al. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. , 1996, Biochemical pharmacology.
[156] D. Lewis,et al. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. , 2000, Biochemical pharmacology.
[157] J. Venhorst,et al. Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening. , 1999, Chemical research in toxicology.
[158] Ismael Zamora,et al. Combining pharmacophore and protein modeling to predict CYP450 inhibitors and substrates. , 2002, Methods in enzymology.
[159] Subhash C. Basak. Binding of barbiturates to cytochrome P450: A QSAR study using log P and topological indices , 1988 .
[160] Ismael Zamora,et al. Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors , 2002, J. Comput. Aided Mol. Des..
[161] Serge Léger,et al. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. , 2002, Biochemistry.
[162] Eamonn F. Healy,et al. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .
[163] R. Remmel,et al. Drug Metabolism Databases and High-Throughput Testing During Drug Design and Development. , 2002 .
[164] Slobodan Petar Rendic,et al. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.
[165] Alexander D. MacKerell,et al. Molecular dynamics simulation of unsaturated lipid bilayers at low hydration: parameterization and comparison with diffraction studies. , 1997, Biophysical journal.
[166] C. Levinthal. How to fold graciously , 1969 .
[167] J N Smith,et al. The comparative metabolism of xenobiotics. , 1968, Advances in comparative physiology and biochemistry.
[168] William L. Jorgensen,et al. Development of an all-atom force field for heterocycles. Properties of liquid pyridine and diazenes , 1998 .
[169] M Pastor,et al. Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. , 1997, Journal of medicinal chemistry.
[170] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[171] M H Tarbit,et al. Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[172] C. Waller,et al. Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[173] A. Y. Lu,et al. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[174] Gunnar Rätsch,et al. Active Learning with Support Vector Machines in the Drug Discovery Process , 2003, J. Chem. Inf. Comput. Sci..
[175] R. Glen,et al. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.
[176] J D GRAHAM,et al. STRUCTURE-ACTION RELATIONS IN N,N-DIMETHYL-2-HALO-GENOPHENETHYLAMINES. , 1963, Journal of medicinal chemistry.
[177] N. Vermeulen,et al. A refined substrate model for human cytochrome P450 2D6. , 1997, Chemical research in toxicology.
[178] J. Halpert,et al. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. , 2001, Biochemistry.
[179] David E. Clark,et al. Evolutionary Algorithms in Molecular Design , 1999 .
[180] C. D. Gelatt,et al. Optimization by Simulated Annealing , 1983, Science.
[181] Gerhard Klebe,et al. Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures , 1994, J. Chem. Inf. Comput. Sci..
[182] David Hartsough,et al. Toward an Optimal Procedure for Variable Selection and QSAR Model Building , 2001, J. Chem. Inf. Comput. Sci..
[183] R D Cramer,et al. Three-dimensional structure-activity relationships. , 1988, Trends in pharmacological sciences.
[184] Svante Wold,et al. Partial least-squares method for spectrofluorimetric analysis of mixtures of humic acid and lignin sulfonate , 1983 .
[185] G. Veith,et al. A QSAR evaluation of Ah receptor binding of halogenated aromatic xenobiotics. , 1996, Environmental health perspectives.
[186] R. Wade,et al. Prediction of drug binding affinities by comparative binding energy analysis. , 1997, Journal of medicinal chemistry.
[187] Young-Sang Choi,et al. Quantitative Structure-Activity Relationships (QSAR) Study of Flavonoid Derivatives for Inhibition of Cytochrome P450 1A2 , 2000 .
[188] Ferran Sanz,et al. 3D-QSAR methods on the basis of ligand–receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands , 2000, J. Comput. Aided Mol. Des..
[189] Sung Jin Cho,et al. Rational Combinatorial Library Design. 1. Focus-2D: A New Approach to the Design of Targeted Combinatorial Chemical Libraries , 1998, J. Chem. Inf. Comput. Sci..
[190] C. Hansch,et al. p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure , 1964 .
[191] Johann Gasteiger,et al. Multivariate structure‐activity relationships between data from a battery of biological tests and an ensemble of structure descriptors: The PLS method , 1984 .
[192] S. Ekins,et al. Progress in predicting human ADME parameters in silico. , 2000, Journal of pharmacological and toxicological methods.
[193] Michel Petitjean,et al. Applications of the radius-diameter diagram to the classification of topological and geometrical shapes of chemical compounds , 1992, J. Chem. Inf. Comput. Sci..
[194] U. Singh,et al. A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS , 1984 .
[195] J. Gasteiger,et al. Autocorrelation of Molecular Surface Properties for Modeling Corticosteroid Binding Globulin and Cytosolic Ah Receptor Activity by Neural Networks , 1995 .
[196] Anton J. Hopfinger,et al. Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships , 1994, J. Chem. Inf. Comput. Sci..
[197] M. Waterman,et al. Evolutionarily divergent electron donor proteins interact with P450MT2 through the same helical domain but different contact points , 2001, The EMBO journal.
[198] J. G. Snijders,et al. Extension of a predictive substrate model for human cytochrome P4502D6. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.
[199] Parr,et al. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.
[200] D. Mansuy,et al. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.
[201] Péter Fábián,et al. The directory of P450-containing systems in 1996 , 1997, Nucleic Acids Res..
[202] M Pastor,et al. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. , 1998, Journal of medicinal chemistry.
[203] C. Yoon,et al. Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. , 1998, Biochemical pharmacology.
[204] Maurice Dickins,et al. Substrate SARs in human P450s. , 2002, Drug discovery today.
[205] William L. Jorgensen,et al. Development of an All-Atom Force Field for Heterocycles. Properties of Liquid Pyrrole, Furan, Diazoles, and Oxazoles , 1998 .
[206] E Baston,et al. Synthesis, evaluation and QSAR studies of highly potent aromatase inhibitors of the piperidinedione type. , 2001, Anti-cancer drug design.
[207] G. Miller,et al. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. , 2000, Biochemistry.
[208] A. Alex,et al. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[209] J. Devillers. Genetic algorithms in molecular modeling , 1996 .
[210] A. Alex,et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[211] C L Brooks,et al. Do active site conformations of small ligands correspond to low free-energy solution structures? , 1998, Journal of computer-aided molecular design.
[212] D. Mansuy,et al. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. , 1996, Biochemistry.
[213] T. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..
[214] P N Judson,et al. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.
[215] Jürgen Bajorath,et al. Distinguishing between Natural Products and Synthetic Molecules by Descriptor Shannon Entropy Analysis and Binary QSAR Calculations , 2000, J. Chem. Inf. Comput. Sci..
[216] Jeffrey P. Jones,et al. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. , 1999, Archives of biochemistry and biophysics.
[217] M H Tarbit,et al. Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives. , 1999, Journal of enzyme inhibition.
[218] D. Nelson,et al. Mining databases for cytochrome P450 genes. , 2002, Methods in enzymology.
[219] Min Zhang,et al. Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. , 2003, Journal of medicinal chemistry.
[220] Johann Gasteiger,et al. Neural networks in chemistry and drug design , 1999 .
[221] T. Halgren,et al. Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules , 1996 .
[222] Thomas A. Halgren,et al. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular. interactions , 1996, J. Comput. Chem..
[223] D. Ferguson,et al. A new approach to probing conformational space with molecular mechanics: Random incremental pulse search , 1989 .
[224] Simon K. Kearsley,et al. An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap , 1990 .
[225] G T Tucker,et al. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. , 2001, The Biochemical journal.
[226] Nello Cristianini,et al. An Introduction to Support Vector Machines and Other Kernel-based Learning Methods , 2000 .
[227] I. Pajeva,et al. Quantitative structure-activity relationship (QSAR) and three-dimensional QSAR analysis of a series of xanthates as inhibitors and inactivators of cytochrome P450 2B1 , 2002, Xenobiotica; the fate of foreign compounds in biological systems.
[228] A. Cammarata,et al. Interrelationship of the regression models used for structure-activity analyses. , 1972, Journal of medicinal chemistry.
[229] David F. V. Lewis,et al. Structure–activity relationship for human cytochrome P450 substrates and inhibitors , 2002, Drug metabolism reviews.
[230] A. Cavalli,et al. Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes. , 1998, Bioorganic & medicinal chemistry.
[231] G Schneider,et al. Artificial neural networks for computer-based molecular design. , 1998, Progress in biophysics and molecular biology.
[232] Johann Gasteiger,et al. Electronegativity equalization: application and parametrization , 1985 .
[233] J. Miners,et al. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.
[234] S. Ekins,et al. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.
[235] György M. Keserü,et al. METAPRINT: A Metabolic Fingerprint. Application to Cassette Design for High-Throughput ADME Screening , 2002, J. Chem. Inf. Comput. Sci..
[236] William L. Jorgensen,et al. A comprehensive study of the rotational energy profiles of organic systems by ab initio MO theory, forming a basis for peptide torsional parameters , 1995, J. Comput. Chem..
[237] Jure Zupan,et al. NEURONALE NETZE IN DER CHEMIE , 1993 .
[238] Bernard Testa,et al. Drug Metabolism: Chemical and Biochemical Aspects , 1976 .
[239] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[240] F. Darvas,et al. Predicting metabolic pathways by logic programming , 1988 .
[241] Tommy B Andersson,et al. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. , 2002, The Journal of pharmacology and experimental therapeutics.
[242] Ramon Carbó-Dorca,et al. Molecular Quantum Similarity-Based QSARs for Binding Affinities of Several Steroid Sets , 2002, J. Chem. Inf. Comput. Sci..
[243] W. R. Wadt,et al. Ab initio effective core potentials for molecular calculations. Potentials for main group elements Na to Bi , 1985 .
[244] S. D. Turner,et al. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[245] W. R. Wadt,et al. Ab initio effective core potentials for molecular calculations , 1984 .
[246] L. Benet,et al. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics , 1996, Clinical pharmacology and therapeutics.
[247] A. Leach. A Survey of Methods for Searching the Conformational Space of Small and Medium‐Sized Molecules , 1992 .
[248] M H Tarbit,et al. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.
[249] S. Ekins,et al. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.
[250] M Karplus,et al. Zinc binding in proteins and solution: A simple but accurate nonbonded representation , 1995, Proteins.
[251] Shen Wang,et al. Construction of a Virtual High Throughput Screen by 4D-QSAR Analysis: Application to a Combinatorial Library of Glucose Inhibitors of Glycogen Phosphorylase b , 1999, J. Chem. Inf. Comput. Sci..
[252] S. Ekins,et al. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[253] J. Halpert,et al. Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. , 1997, Life sciences.